DBV Technologies S.A. News
DBV Technologies Spikes on Positive FDA Communication
DBV says it received positive feedback concerning its peanut allergy treatment.
Endurance International, Farfetch: 5 Top Stock Gainers for Monday
Endurance International, DBV Technologies, Farfetch, Lumber Liquidators and Insperity are five top stock gainers for Monday
DBV Soars on European Validation of Peanut Allergy Patch Application
DBV said it expects to receive the first set of questions from the EMA regarding marketing approval about 120 days post-validation.
DBVT Rises On New Data For Peanut Allergy Drug; Bitcoin Rockets Past $8,000 -- ICYMI
Here's what you need to know now for Monday, Nov. 20.
The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI
Here's what you need to know now for Monday, Oct. 23.
Biotech Movers: Synergy Pharmaceuticals Explodes 15%, and Bluebird Bio May Be Next
Synergy Pharmaceuticals, Bluebird Bio and DBV Technologies were among the biotech stock movers in early trading on Friday.
These Stocks Are Trending Up With Monster Volume
Let's take a look at several stocks that are experiencing unusual volume activity.
7 Stocks Trending Up With Monster Volume
Here's a technical look at how to play a number of stocks trending higher with strong volume.
7 stocks spiking on big volume--here's how to trade them
These stocks rising on unusual volume are within range of triggering big breakout trades.
5 Stocks Ready for Breakouts
These stocks look poised to break out and trade higher from current levels.
Breaking News
Johnson & Johnson Stock Lower After Unveiling End To Global Baby Powder Sales In 2023
Johnson & Johnson, which began selling Baby Powder in 1894, will end all sales of the talc-based product next year.
Apple Stock Edges Higher After Report Indicates iPhone Demand Confidence
Apple is asking assemblers to put together 220 million iPhones this year, Bloomberg reported, a tally that largely matches 2021 levels.
Struggling Electric-Truck Maker Nikola Makes a Major Change
Electric-truck manufacturer Nikola, like the broad vehicle industry, has been struggling with supply-chain issues.
Illumina and the Quest for the (Holy?) Grail
DNA-sequencing leader Illumina swung to a loss in Q2 2022. Contributions from Grail didn't help.